ly3041658
Small moleculeexperimental
Clinical trial activity
6 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Jun 16, 2014 (NCT02148627)
Timeline
Indications
Mechanism of action
- Chemokine XC receptor 1INHIBITOR
XCR1 inhibitor
- Interleukin-8 receptor BINHIBITOR
CXCR2 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5314628 ↗
Also known as
- ly3041658
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06598943 | Phase 2 | Oct 10, 2024 | Eli Lilly |
| NCT06046729 | Phase 2 | Oct 23, 2023 | Eli Lilly |
| NCT04653168 | Phase 1 | Dec 7, 2020 | Eli Lilly |
| NCT04493502 | Phase 2 | Aug 26, 2020 | Eli Lilly |
| NCT02896868 | Phase 1 | Nov 8, 2016 | Eli Lilly |
| NCT02148627 | Phase 1 | Jun 16, 2014 | Eli Lilly |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Eli Lilly | For profit | 6 | 6 | 2 | 2014 |
1 organizations
Page 1 / 1